Physician profile
Catherine R Kilpatrick
NPI 1649407354
$689,863.63
in general payments reported to CMS, 2019-2025
45 companies · $113K in 2025
The $113K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133K · 2020: $58K · 2021: $80K · 2022: $86K · 2023: $113K · 2024: $108K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $82K · Travel and Lodging: $42K · Food and Beverage: $12K · Consulting Fee: $900 · Education: $64.50 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196,040.30 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $82,373.75 |
| Travel and Lodging | $41,699.00 |
| Food and Beverage | $11,863.86 |
| Consulting Fee | $900.00 |
| Education | $64.50 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216,998.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $126,389.31 | 2019-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $121,175.33 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $114,504.31 | 2019-2025 | |
| Abbott Laboratories | $81,520.57 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Proclaim |
| Lilly USA, LLC | $24,055.32 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Medtronic Minimed, INC. | $1,453.53 | 2019-2020 | |
| Beta Bionics, INC. | $368.49 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Kyowa Kirin, INC. | $350.40 | 2023-2025 | Crysvita |
| Tandem Diabetes Care, INC. | $253.00 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $231.08 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.64 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $212.53 | 2022 | |
| Insulet Corporation | $204.41 | 2020-2025 | Omnipod |
| Neurocrine Biosciences, INC. | $183.03 | 2024-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Kilpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.